Mechanisms of Tropomyosin 3 in the Development of Malignant Tumors

Overview

Journal Heliyon

Specialty Social Sciences

Date 2024 Aug 22

PMID 39170461

Authors

Anjie Chen

Sixin Li

Jiandong Gui

Hangsheng Zhou

Lijie Zhu

Yuanyuan Mi

Affiliations

Soon will be listed here.

Abstract

Tropomyosin (TPM) is an important regulatory protein that binds to actin in fine myofilaments, playing a crucial role in the regulation of muscle contraction. TPM3, as one of four tropomyosin genes, is notably prevalent in eukaryotic cells. Traditionally, abnormal gene expression of TPM3 has been exclusively associated with myopathy. However, recent years have witnessed a surge in studies highlighting the close correlation between abnormal expression of TPM3 and the onset, progression, metastasis, and prognosis of various malignant tumors. In light of this, investigating the mechanisms underlying the pathogenetic role of TPM3 holds significant promise for early diagnosis and more effective treatment strategies. This article aims to provide an insightful review of the structural characteristics of TPM3 and its intricate role in the occurrence and development of malignant tumors.

References

Ardini E, Bosotti R, Borgia A, De Ponti C, Somaschini A, Cammarota R . The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol. 2014; 8(8):1495-507. PMC: 5528583. DOI: 10.1016/j.molonc.2014.06.001. View

Schreckenbach T, Schroder J, Voit T, Abicht A, Neuen-Jacob E, Roos A . Novel TPM3 mutation in a family with cap myopathy and review of the literature. Neuromuscul Disord. 2013; 24(2):117-24. DOI: 10.1016/j.nmd.2013.10.002. View

Rabban J, Devine W, Sangoi A, Poder L, Alvarez E, Davis J . NTRK fusion cervical sarcoma: a report of three cases, emphasising morphological and immunohistochemical distinction from other uterine sarcomas, including adenosarcoma. Histopathology. 2020; 77(1):100-111. DOI: 10.1111/his.14069. View

Caldwell B, Lucas C, Kee A, Gaus K, Gunning P, Hardeman E . Tropomyosin isoforms support actomyosin biogenesis to generate contractile tension at the epithelial zonula adherens. Cytoskeleton (Hoboken). 2014; 71(12):663-76. DOI: 10.1002/cm.21202. View

Gerami P, Kim D, Compres E, Zhang B, Khan A, Sunshine J . Clinical, morphologic, and genomic findings in ROS1 fusion Spitz neoplasms. Mod Pathol. 2020; 34(2):348-357. PMC: 7855005. DOI: 10.1038/s41379-020-00658-w. View

Matyushenko A, Levitsky D . Molecular Mechanisms of Pathologies of Skeletal and Cardiac Muscles Caused by Point Mutations in the Tropomyosin Genes. Biochemistry (Mosc). 2020; 85(Suppl 1):S20-S33. DOI: 10.1134/S0006297920140023. View

Lee J, Li C, Huang H, Zhu M, Marino-Enriquez A, Lee C . ALK oncoproteins in atypical inflammatory myofibroblastic tumours: novel RRBP1-ALK fusions in epithelioid inflammatory myofibroblastic sarcoma. J Pathol. 2016; 241(3):316-323. PMC: 5337428. DOI: 10.1002/path.4836. View

McMichael B, Lee B . Tropomyosin 4 regulates adhesion structures and resorptive capacity in osteoclasts. Exp Cell Res. 2007; 314(3):564-73. PMC: 2254556. DOI: 10.1016/j.yexcr.2007.10.018. View

Giuriato S, Faumont N, Bousquet E, Foisseau M, Bibonne A, Moreau M . Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biol Ther. 2007; 6(8):1318-23. DOI: 10.4161/cbt.6.8.4508. View

10.

Park S, Ahn B, Lim S, Sun J, Kim H, Hong M . Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice. J Thorac Oncol. 2018; 13(9):1373-1382. DOI: 10.1016/j.jtho.2018.05.026. View

11.

Zhang P, Zhang W, Jiang J, Shen Z, Chen S, Yu S . MiR-107 inhibits the malignant biological behavior of esophageal squamous cell carcinoma by targeting TPM3. J Gastrointest Oncol. 2022; 13(4):1541-1555. PMC: 9459194. DOI: 10.21037/jgo-22-575. View

12.

Borovikov Y, Avrova S, Karpicheva O, Robinson P, Redwood C . The effect of the dilated cardiomyopathy-causing Glu40Lys TPM1 mutation on actin-myosin interactions during the ATPase cycle. Biochem Biophys Res Commun. 2011; 411(3):496-500. DOI: 10.1016/j.bbrc.2011.06.138. View

13.

Busam K, Kutzner H, Cerroni L, Wiesner T . Clinical and pathologic findings of Spitz nevi and atypical Spitz tumors with ALK fusions. Am J Surg Pathol. 2014; 38(7):925-33. PMC: 5042334. DOI: 10.1097/PAS.0000000000000187. View

14.

Surabhi V, Chua S, Patel R, Takahashi N, Lalwani N, Prasad S . Inflammatory Myofibroblastic Tumors: Current Update. Radiol Clin North Am. 2016; 54(3):553-63. DOI: 10.1016/j.rcl.2015.12.005. View

15.

Schevzov G, Bryce N, Almonte-Baldonado R, Joya J, Lin J, Hardeman E . Specific features of neuronal size and shape are regulated by tropomyosin isoforms. Mol Biol Cell. 2005; 16(7):3425-37. PMC: 1165423. DOI: 10.1091/mbc.e04-10-0951. View

16.

Chen S, Shen Z, Gao L, Yu S, Zhang P, Han Z . TPM3 mediates epithelial-mesenchymal transition in esophageal cancer via MMP2/MMP9. Ann Transl Med. 2021; 9(16):1338. PMC: 8422148. DOI: 10.21037/atm-21-4043. View

17.

Bonnet A, Lambert G, Ernest S, Dutrieux F, Coulpier F, Lemoine S . Quaking RNA-Binding Proteins Control Early Myofibril Formation by Modulating Tropomyosin. Dev Cell. 2017; 42(5):527-541.e4. DOI: 10.1016/j.devcel.2017.08.004. View

18.

Pieples K, Arteaga G, Solaro R, Grupp I, Lorenz J, Boivin G . Tropomyosin 3 expression leads to hypercontractility and attenuates myofilament length-dependent Ca(2+) activation. Am J Physiol Heart Circ Physiol. 2002; 283(4):H1344-53. DOI: 10.1152/ajpheart.00351.2002. View

19.

Gatalica Z, Xiu J, Swensen J, Vranic S . Molecular characterization of cancers with NTRK gene fusions. Mod Pathol. 2018; 32(1):147-153. DOI: 10.1038/s41379-018-0118-3. View

20.

Schevzov G, Vrhovski B, Bryce N, Elmir S, Qiu M, ONeill G . Tissue-specific tropomyosin isoform composition. J Histochem Cytochem. 2005; 53(5):557-70. DOI: 10.1369/jhc.4A6505.2005. View